Peter Brünker
Hoffmann-La Roche
23 Papers
46 Citations
Peter Brünker is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Antibody & T cell. The author has an hindex of 11, co-authored 23 publications.
Chat about Author
Papers
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
Ekkehard Mössner,Peter Brünker,Samuel Moser,Ursula Püntener,Carla Schmidt,Sylvia Herter,Roger Grau,Christian Gerdes,Adam Nopora,Erwin van Puijenbroek,Claudia Ferrara,Peter Sondermann,Christiane Jäger,Pamela Strein,Georg Fertig,Thomas Friess,Christine Schüll,Sabine Bauer,Joseph Dal Porto,Christopher Del Nagro,Karim Dabbagh,Martin J. S. Dyer,Sibrand Poppema,Christian Klein,Pablo Umana +24 more
TL;DR: In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival and in nonhuman primates, GA 101 demonstrates superior B cell-depleting activity in lymphoid tissue, including in lymph nodes and spleen.
965
Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
Claudia Ferrara,Sandra Grau,Christiane Jäger,Peter Sondermann,Peter Brünker,Inja Waldhauer,Michael Hennig,Armin Ruf,Arne C. Rufer,Martine Stihle,Pablo Umana,Jörg Benz +11 more
TL;DR: A detailed, molecular understanding of the regulatory role of Fc-oligosaccharide core fucosylation in improving ADCC is obtained and a unique mechanism by which the immune system can regulate antibody-mediated effector functions is suggested.
756
Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II
TL;DR: The results indicate that chimeric GnT‐III can compete even more efficiently against the endogenous core α1,6‐fucosyltransferase (α1, 6‐FucT) and Golgi α‐mannosidase II (ManII) leading to higher proportions of bisected non‐fukosylated hybrid glycans (“Glyco‐1” antibody).
370
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Christian Klein,Inja Waldhauer,Nicolini Valeria G,Anne Freimoser-Grundschober,Tapan K. Nayak,Danielle J. Vugts,Claire Dunn,Marije Bolijn,Jörg Benz,Martine Stihle,Sabine Lang,Michaele Roemmele,Hofer Thomas U,Erwin van Puijenbroek,David Wittig,Samuel Moser,Oliver Ast,Peter Brünker,Ingo H. Gorr,Sebastian Neumann,Maria Cristina De Vera Mudry,Heather Hinton,Flavio Crameri,Jose Saro,Stefan Evers,Christian Gerdes,Marina Bacac,Guus A.M.S. van Dongen,Ekkehard Moessner,Pablo Umana +29 more
TL;DR: Preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
245
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Christina Claus,Claudia Ferrara,Wei Xu,Johannes Sam,Sabine Lang,Franziska Uhlenbrock,Rosmarie Albrecht,Sylvia Herter,Ramona Schlenker,Tamara Hüsser,Sarah Diggelmann,John Challier,Ekkehard Mössner,Ralf Hosse,Hofer Thomas U,Peter Brünker,Catherine Joseph,Jörg Benz,Philippe Ringler,Henning Stahlberg,Matthias E. Lauer,Mario Perro,Stanford Chen,Christine Küttel,Preethi Latha Bhavani Mohan,Nicolini Valeria G,Martina Carola Birk,Amandine Ongaro,Christophe Prince,Reto Gianotti,Gregory O. Dugan,Christopher T. Whitlow,Kiran Kumar Solingapuram Sai,David L. Caudell,Armando G. Burgos-Rodriguez,J. Mark Cline,Michael Hettich,Maurizio Ceppi,Anna Maria Giusti,Flavio Crameri,Wouter H. P. Driessen,Peter N. Morcos,Anne Freimoser-Grundschober,Victor Levitsky,Maria Amann,Sandra Grau-Richards,Thomas von Hirschheydt,Stella Tournaviti,Michael Molhoj,Tanja Fauti,Viola Heinzelmann-Schwarz,Volker Teichgräber,Sara Colombetti,Marina Bacac,Alfred Zippelius,Christian Klein,Pablo Umana +56 more
TL;DR: FAP– and CD19–4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.
230